# Phase 3 Lung Diseases trials recruiting: 24 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials in phase 3 for Lung Diseases that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Lung Diseases trials: 24 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/lung-diseases

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 24
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 18, 2026 | NCT07828054 | Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan | Mario Negri Institute for Pharmacological Research | Phase 3 | Not yet recruiting | Breast Cancer, Interstitial Lung Disease (ILD) | 244 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828054) |
| September 11, 2026 | NCT07816185 | A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier) | Pulmovant, Inc. | Phase 3 | Recruiting | Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases, Fibrosis | 376 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816185) |
| September 4, 2026 | NCT07805785 | A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary... | Insmed Incorporated | Phase 3 | Recruiting | Progressive Pulmonary Fibrosis, Interstitial Lung Disease | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805785) |
| May 29, 2026 | NCT07613099 | Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | Recruiting | Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury... | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07613099) |
| April 29, 2026 | NCT07555483 | A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With... | Grifols Therapeutics LLC | Phase 3 | Recruiting | Alpha 1 Antitrypsin Deficiency | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555483) |
| April 21, 2026 | NCT07540988 | FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression | Boehringer Ingelheim | Phase 3 | Recruiting | Interstitial Lung Diseases | 466 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07540988) |
| December 16, 2025 | NCT07285655 | A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD | Liquidia Technologies, Inc. | Phase 3 | Recruiting | Pulmonary Hypertension Due to Lung Disease (Disorder) | 344 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285655) |
| December 16, 2025 | NCT07284602 | Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis... | PureTech | Phase 3 | Recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 1,100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284602) |
| November 18, 2025 | NCT07234032 | An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With... | Insmed Incorporated | Phase 3 | Recruiting | Pulmonary Hypertension, Interstitial Lung Disease | 344 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07234032) |
| October 1, 2025 | NCT07201922 | A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis | Boehringer Ingelheim | Phase 3 | Recruiting | Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07201922) |
| September 17, 2025 | NCT07179380 | Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With... | Insmed Incorporated | Phase 3 | Recruiting | Pulmonary Hypertension, Interstitial Lung Disease | 344 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07179380) |
| June 26, 2025 | NCT07039669 | Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 3 | Recruiting | Pulmonary Disease, Chronic Obstructive (COPD) | 594 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07039669) |
| June 10, 2025 | NCT07013474 | A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | Pfizer | Phase 3 | Recruiting | COVID-19 Infection | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07013474) |
| January 9, 2025 | NCT06765109 | Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | Nuvalent Inc. | Phase 3 | Recruiting | Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06765109) |
| December 4, 2024 | NCT06716606 | A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With... | GlaxoSmithKline | Phase 3 | Recruiting | Connective Tissue Diseases | 514 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06716606) |
| November 7, 2024 | NCT06679140 | A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are... | Pfizer | Phase 3 | Recruiting | COVID-19 SARS-CoV-2 Infection | 2,330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06679140) |
| August 27, 2024 | NCT06572384 | A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease | GlaxoSmithKline | Phase 3 | Recruiting | Lung Diseases, Interstitial | 440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06572384) |
| May 28, 2024 | NCT06431633 | Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who... | Fundación GECP | Phase 3 | Recruiting | Lung Diseases, Carcinoma, Non-Small-Cell Lung, Resectable Lung Non-Small Cell Carcinoma | 129 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06431633) |
| March 6, 2024 | NCT06297096 | Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | Phase 3 | Recruiting | Systemic Sclerosis, Interstitial Lung Disease | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06297096) |
| February 12, 2024 | NCT06253715 | Shortened Regimen for Drug-susceptible TB in Children | Johns Hopkins University | Phase 3 | Recruiting | Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node, Mycobacterium Tuberculosis | 860 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06253715) |
| November 7, 2023 | NCT06119581 | A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant... | Eli Lilly and Company | Phase 3 | Recruiting | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 1,264 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06119581) |
| July 13, 2023 | NCT05943535 | Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | United Therapeutics | Phase 3 | Recruiting | Progressive Pulmonary Fibrosis, Interstitial Lung Disease | 698 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05943535) |
| November 22, 2022 | NCT05624450 | Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | AstraZeneca | Phase 3 | Recruiting | Viral Lung Infection and Acute Respiratory Failure | 3,527 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05624450) |
| April 13, 2016 | NCT02735707 | Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | UMC Utrecht | Phase 3 | Recruiting | Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia... | 20,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02735707) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Insmed Incorporated](https://specstream.ai/data/clinical-trials/company/insmed-incorporated) | 3 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 2 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 2 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 2 |
| Nuvalent Inc. | 1 |
| UMC Utrecht | 1 |
| [United Therapeutics](https://specstream.ai/data/clinical-trials/company/united-therapeutics) | 1 |
| Pulmovant, Inc. | 1 |
| Liquidia Technologies, Inc. | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 1 |
| PureTech | 1 |
| [Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sunshine-guojian-pharmaceutical-shanghai-co-ltd) | 1 |
| National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | 1 |
| Johns Hopkins University | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | 1 |
| Mario Negri Institute for Pharmacological Research | 1 |
| Fundación GECP | 1 |
| [Grifols Therapeutics LLC](https://specstream.ai/data/clinical-trials/company/grifols-therapeutics-llc) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 19 |
| Spain | 15 |
| Germany | 14 |
| France | 13 |
| Belgium | 12 |
| Japan | 12 |
| South Korea | 12 |
| Australia | 11 |
| Canada | 11 |
| United Kingdom | 11 |
| Argentina | 10 |
| Italy | 10 |
| Brazil | 8 |
| Mexico | 8 |
| Netherlands | 8 |
| Taiwan | 8 |
| Czechia | 7 |
| Denmark | 7 |
| Greece | 7 |
| Poland | 7 |
| China | 7 |
| Portugal | 6 |
| Austria | 5 |
| Israel | 5 |
| Turkey (Türkiye) | 5 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B industrial and machine companies in the United States](https://specstream.ai/data/businesses/b2b-industrial-and-machine-companies/united-states)
- [Private jet charter companies in the United States](https://specstream.ai/data/businesses/private-jet-charter-companies/united-states)
- [Garage door companies in the United States](https://specstream.ai/data/businesses/garage-door-companies/united-states)
- [B2B food products companies in the United States](https://specstream.ai/data/businesses/b2b-food-products-companies/united-states)
- [Private investigators in the United States](https://specstream.ai/data/businesses/private-investigators/united-states)
- [Furniture wholesalers in the United States](https://specstream.ai/data/businesses/furniture-wholesalers/united-states)
